Prevacid · DIN 02165511 · 30 mg · DR capsule
Limited Use, Reason for Use code 293, 295, 297, 401, 402 requiredMarketed · checked November 17, 2026
StatusLimited Use, Reason for Use code 293, 295, 297, 401, 402 required
Write on scriptone applicable Reason for Use code, 293 or 295 or 297 or 401 or 402 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 293, 295, 297, 401, 402
Reason for Use code 293
Gastroesophageal Reflux Disease (GERD)
For the treatment of erosive GERD or upper GI malignancy; OR
For the treatment of non-erosive GERD after failure of H2-receptor antagonist therapy.
Patients with GERD should be reassessed within 6 months after initial treatment with a PPI. The reassessment could include confirmation of need for PPI with endoscopy, a trial of PPI withdrawal, or step-down therapy to H2-receptor antagonist therapy.
Note: There is a lack of published evidence to support double-dose PPI therapy in this setting.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 295
H. pylori-positive Peptic Ulcers
For the treatment of H. pylori-positive peptic ulcers where H. pylori is documented, by serology, urea breath test or endoscopy, for a course of up to 14 days in combination with antimicrobial therapy. Retreatment of H. pylori-positive peptic ulcers must be documented by persistent H. pylori infection on urea breath test or endoscopy.
Maximum duration: 14 days (for retreatment, a four-week period must elapse since the end of the previous treatment).
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 297
Confirmed Peptic Ulcers or NSAID-induced Ulcer Prophylaxis:
For the treatment of confirmed peptic ulcers and NSAID-induced ulcers; OR
For the prophylaxis of NSAID-induced ulcers for patients at increased risk of GI bleeding.
Note: There is a lack of published evidence to support double-dose PPI therapy in this setting.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 401
Other Gastrointestinal Disorders:
For the treatment of gastroduodenal Crohns disease, short-gut syndrome, scleroderma, or pancreatitis.
Note: There is a lack of published evidence to support double-dose PPI therapy in these settings.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 402
Severe Conditions:
For the treatment of severe esophagitis, Zollinger-Ellison syndrome, esophageal stricture, persistent symptoms of GERD or persistent erosive esophagitis, or upon hospital discharge following a gastrointestinal bleed.
For patients receiving double-dose therapy, the need to continue treatment at higher doses should be reassessed after eight weeks. For re-treatment at higher doses, a four-week period should have elapsed from the end of the previous treatment. Reassessment could include a procedural assessment of the condition or step-down therapy to lower-dose proton pump inhibitor (PPI) therapy.
Coverage limit:
LU Authorization Period: 1 year
Savings card: RxHelp ONE lists Prevacid (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Prevacid · DIN 02165511
Manufacturer: Takeda Pharmaceuticals America Inc.; listing date 1996-10-01
Health Canada: Marketed since 2008-10-10 · brand PREVACID · ATC A02BC03 LANSOPRAZOLE · form Capsule (delayed-release) · route Oral · ingredients LANSOPRAZOLE 30 MG · company Takeda pharmaceuticals america inc · schedule Prescription
Ministry pays: $0.5000 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02165511)
Source record
DIN 02165511: Prevacid
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 564000073; group id 680; item number 1697; lccId 00103; manufacturer id TPA
Source form: DR Cap; strength: 30mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $2.4874; ministry $0.5000
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02165511
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18516
Interchangeable products
Apo-Lansoprazole · DIN 02293838 · $0.5000
Lansoprazole · DIN 02357690 · $0.5000
Lansoprazole · DIN 02410389 · $0.5000
Mylan-Lansoprazole · DIN 02353849 · $0.5000
Sandoz Lansoprazole · DIN 02385651 · $0.5000
Taro-Lansoprazole · DIN 02402629 · $0.5000
Teva-Lansoprazole · DIN 02280523 · $0.5000
Shortage status: avoided shortage; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02165511
Shortage record checked October 6, 2026